Our News

Presentations & Publications

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture

Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

Concarlo in the News

US biotech start-up set to have huge impact on breast cancer treatment landscape

Concarlo: targeting proliferation and resistance in one go

Patent awarded for Concarlo-developed therapeutic to tackle treatment-resistant breast cancer

Women & Wealth Magazine: 18 Women to Watch in 2018

Webinars & Talks

Targeting p27Kip1 to Treat Drug-Resistance Cancer

Opportunity to Join the Fight Against Metastatic Breast Cancer

Concarlo is on a Mission to Rid the World of Metastatic Breast Cancer

Awards

“The reward for work well done is the opportunity to do more”

—Jonas Salk

The 50 Most admired companies: CIO Bio

Top 100 entreprenuers: Alumni List

Top Biotech Startup 2022
Awarded by: Life Sciences Review